ArticleAntimicrobial agents and chemotherapy1993
In vitro activity of azithromycin against bacterial enteric pathogens.
Article in Antimicrobial agents and chemotherapy, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 55 citations in OpenAlex.
- Effect of Antenatal Monthly Sulfadoxine-Pyrimethamine, Alone or with Azithromycin, on Gestational Weight Gain and Anemia during Pregnancy and One Month Postpartum in Malawi: A Randomized Controlled Trial Secondary Analysis.The American journal of tropical medicine and hygiene · 2025Trial
- Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of Escherichia coli and Klebsiella pneumoniae in Mothers and Their Newborns: A Substudy of a Randomized, Double-Blind Trial Conducted in The Gambia and Burkina Faso.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Plasma concentration of azithromycin and correlation with clinical outcomes in patients with enteric fever.JAC-antimicrobial resistance · 2025Article
- Genetic Characterization of a Conjugative Plasmid That Encodes Azithromycin Resistance inMicrobiology spectrum · 2022Article
- Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome in children: a randomized, controlled trial.Gut pathogens · 2022Article
- Treatment of EnteropathogenicCase reports in infectious diseases · 2018Article
- Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.Clinical microbiology reviews · 2015Review
- Salmonella subtypes with increased MICs for azithromycin in travelers returned to The Netherlands.Emerging infectious diseases · 2014Article
- Quinolone and cephalosporin resistance in enteric Fever.Journal of global infectious diseases · 2010Article
- STATEMENT ON PEDIATRIC TRAVELLERS: Committee to Advise on Tropical Medicine and Travel.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2010Article
- Escherichia coli as reservoir for macrolide resistance genes.Emerging infectious diseases · 2009Article
- Macrolide-resistant Shigella sonnei.Emerging infectious diseases · 2008Article
- Options for treating resistant Shigella species infections in children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2008Article
- Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Paediatric drugs · 2001Review
- Review
- Intracellular activity of azithromycin against bacterial enteric pathogens.Antimicrobial agents and chemotherapy · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activity of azithromycin against enteric bacterial pathogens was determined by agar dilution. Azithromycin was highly active against Campylobacter spp. (MIC for 90% of strains tested [MIC90] = 0.125 micrograms/ml) and against enterotoxigenic, enterohemorrhagic, enteroinvasive, and enteropathogenic Escherichia coli (MIC90 = 2 micrograms/ml), Shigella spp. (MIC90 = 1 micrograms/ml), and Salmonella spp. (MIC90 = 4 micrograms/ml), including Salmonella typhi (MIC90 = 1 microgram/ml). On the basis of the in vitro activity of the drug against these organisms, clinical studies of azithromycin in enteric diseases should be considered; the high intracellular concentrations achieved by azithromycin may be particularly relevant for organisms like S. typhi, Campylobacter spp., and Shigella spp. which typically invade cells as part of their infectious process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.